Almirall’s Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults

 Almirall’s Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults

Almirall’s Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults

Shots:

  • Ilumetri’s (tildrakizumab) approval is based on the positive results from reSURFACE 1 and 2 P-III clinical trial, testing its safety and efficacy in >200 clinical sites worldwide
  • reSURFACE 1 and 2 P-III Results (N=1800): 63% achieved PASI 75@12wks.; ~78% @28 wks., ~59% achieved PASI 90 and ~30% achieved PASI 100 @28wks.; 92% patients were consistent at PASI 75 while maintaining its tolerability and efficacy
  • In 2016, Sun Pharma out-licensed European rights of Ilumetri to Almirall for its development and commercialization for the treatment of psoriasis. Ilumetri is a humanized, anti-IL-23p19 monoclonal Ab, expected to be launched in next few weeks

Click here to read full press release/ article | Ref: Sun Pharma | Image: Fierce Pharma

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post